ALLUVI: A DEEP DIVE INTO RETATRUTIDE'S PROMISE

Alluvi, initially dubbed LY3414901, represents a exciting advancement in obesity management. This dual -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist shows remarkable effectiveness in early medical data, with substantial weight loss